These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 29448882

  • 1. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

  • 2. Low-dose cyclosporine for active lupus nephritis: a dose titration approach.
    Sumethkul K, Kitumnuaypong T, Angthararak S, Pichaiwong W.
    Clin Rheumatol; 2019 Aug; 38(8):2151-2159. PubMed ID: 30937637
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A.
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [Abstract] [Full Text] [Related]

  • 4. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A.
    BMC Nephrol; 2018 Jul 11; 19(1):175. PubMed ID: 29996800
    [Abstract] [Full Text] [Related]

  • 5. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.
    Kasitanon N, Boripatkosol P, Louthrenoo W.
    Int J Rheum Dis; 2018 Jan 11; 21(1):200-207. PubMed ID: 28901731
    [Abstract] [Full Text] [Related]

  • 6. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan 11; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep 11; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB, Won S, Bae SC.
    Lupus; 2018 May 11; 27(6):1007-1011. PubMed ID: 29448881
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB, Kang YM, Kim HA, Suh CH, Kim TJ, Park YW, Lee J, Lee JH, Yoo DH, Bae SC, Lee HS, Bang SY.
    Int J Rheum Dis; 2018 May 11; 21(5):1031-1039. PubMed ID: 29611341
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S, Gupta D, Ali S, Gupta P.
    Saudi J Kidney Dis Transpl; 2017 May 11; 28(5):1069-1077. PubMed ID: 28937065
    [Abstract] [Full Text] [Related]

  • 13. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L.
    Lupus; 2007 May 11; 16(9):707-12. PubMed ID: 17728363
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R, Kurasawa T, Nishi E, Kondo T, Okada Y, Shibata A, Nishimura K, Chino K, Okuyama A, Takei H, Nagasawa H, Amano K.
    Lupus; 2018 Feb 11; 27(2):273-282. PubMed ID: 28683654
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil for remission induction in severe lupus nephritis.
    Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D, Renal Association Clinical Trials Subcommittee.
    Nephron Clin Pract; 2005 Feb 11; 100(3):c92-100. PubMed ID: 15824513
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E, Resontoc LP, Chan YH, Lau YW, Tan PH, Loh HL, Ng KH, Yap HK.
    Lupus; 2016 Apr 11; 25(4):399-406. PubMed ID: 26537422
    [Abstract] [Full Text] [Related]

  • 18. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H, Mushtaq MS, Salim B, Samreen S, Nasim A, Khan M.
    J Ayub Med Coll Abbottabad; 2020 Apr 11; 32(4):454-458. PubMed ID: 33225643
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.
    Ann Rheum Dis; 2016 Jan 11; 75(1):30-6. PubMed ID: 25550339
    [Abstract] [Full Text] [Related]

  • 20. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
    Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A.
    Mod Rheumatol; 2018 May 11; 28(3):523-529. PubMed ID: 28753077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.